阈值下微脉冲激光治疗中心性浆液性脉络膜视网膜病的研究进展  

Research Progress on Subthreshold Micropulse Laser Photocoagulation for Central Serous Chorioretinopathy

作　　者：张晋荣 张悦[1,3] 宋爽[1] 喻晓兵[1] ZHANG Jinrong;ZHANG Yue;SONG Shuang;YU Xiaobing(Department of ophthalmology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;the Fifth School of Clinical Medicine,Peking University;Peking Union Medical Collega Hospital,Chinese Academy of Medical Sciences)

机构地区：[1]北京医院眼科·国家老年医学中心·中国医学科学院老年医学研究所,北京市100730 [2]北京大学第五临床医学院 [3]中国医学科学院北京协和医学院

出　　处：《中国激光医学杂志》2025年第1期50-56,共7页Chinese Journal of Laser Medicine & Surgery

基　　金：中央高水平医院临床科研业务费专项临床研究专项(BJ-2024-089)。

摘　　要：中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy,CSCR)是常见的引起视力损害的视网膜疾病,其特征是黄斑部视网膜色素上皮层局限性浆液性脱离。阈值下微脉冲激光(subthreshold micropulse laser photocoagulation,SMLP)通过多种作用机制促进视网膜下液(subretinal fluid,SRF)吸收,并具有良好的疗效和安全性。本文综述了SMLP与光动力疗法(photodynamic therapy,PDT)、传统激光及抗血管内皮生长因子(anti-vascular endothelial growth factor,VEGF)药物治疗CSCR的对比研究新进展,分析了不同治疗方法的适用情况及选择优势。综合治疗CSCR的风险和获益,SMLP有广阔的应用前景。Central serous chorioretinopathy(CSCR)is a common retinal disease that causes the impairment of vision.It is characterized by localized serous detachment of retinal pigment epithelium in macular areas.Subthreshold micropulse laser photocoagulation(SMLP)promotes the absorption of subretinal fluid(SRF)through various mechanisms of action with good efficacy and safety.In this paper,recent progress in comparative study of SMLP and photodynamic therapy(PDT),conventional laser and anti-vascular endothelial growth factor(VEGF)drugs in the treatment of CSCR was reviewed and the applicability and selective advantages of different therapies were analyzed.Based on the generalization of the risks and benefits in the treatment of CSCR,it is concluded in this paper that SMLP has a broad application prospect.

关 键 词：阈值下微脉冲激光 中心性浆液性脉络膜视网膜病变 对比研究 综述 

分 类 号：R779.63[医药卫生—眼科]